StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) income statement

RDHLNasdaqPharmaceutical Preparations
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.35+0.00 (0.00%)

Close on Nov 18, 2026Market cap $1.78MP/E –Yield –

RedHill Biopharma Ltd. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
–
Operating margin
-2776.9%
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
0.34
Debt to equity
–
Debt to assets
–
Cash to current liabilities
20.2%

Valuation

P/E ratio
–
Price to sales
6.23
Price to book
–
Dividend yield
–

See a number that looks wrong?